News
Home  >  News > New spin-off in the field of precision oncology: Oniria Therapeutics

New spin-off in the field of precision oncology: Oniria Therapeutics

 

 

24/03/2022

Recerca

The Vall d’Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA) joined forces to work on a new project: Oniria Therapeutics. This biopharmaceutical company under preclinical phase aims to develop innovative drugs in the field of precision oncology.

 

 

 

In particular, the new spin-off, which counted on the financial aid of “la Caixa” Foundation, the Spanish Association against Cancer and the Carlos III Health Institute (ISCIII) will focus the effort on the development of therapies to remove persistent cancer cells that are resisting the conventional treatments and which are responsible for the patients’ relapses and their progression towards more advanced stages of the illness.

Among the several projects under development, the most advanced drug is a first-in-class one that acts by modulating the function of the epigenetic factor TET2. This factor drives the global activity of the genome by regulating its methylation profile and forces the cancer cell to “fall asleep” without losing the future malignant potential.

Further information

Share this at:
| More |
  • Follow us:
  • Button to access University of Barcelona's Facebook profile
  • Button to access University of Barcelona's Twitter profile
  • Button to access University of Barcelona's Instagram profile
  • Button to access University of Barcelona's Linkedin profile
  • Button to access University of Barcelona's Youtube profile
  • Button to access University of Barcelona's Google+ profile
  • ??? peu.flickr.alt ???
Member of International recognition of excellence HR Excellence in Research logo del leru - League of European Research Universities logo del bkc - campus excel·lència logo del health universitat de barcelona campus

© Universitat de Barcelona